ReviewCardiovascular drugs and therapy2026
Extracellular Vesicles in Cardiac Cell Crosstalk: from Intercellular Communication to Clinical Translation.
Review in Cardiovascular drugs and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- ANRIL in Cardiovascular Diseases: Expression, Mechanism and Therapeutic Implications.Cardiovascular drugs and therapy · 2026Review
- Extracellular Vesicles: Classification, Biological Functions, Diseases, and Therapeutic Opportunities.MedComm · 2026Review
- Endophenotyping Without Anchors: Operational and Evidentiary Gaps in the Stroke-Heart Syndrome Framework.Cardiovascular drugs and therapy · 2026Article
- Spatiotemporal Nanotherapy After Myocardial Infarction: Targeting the Inflammatory-to-reparative Transition With Extracellular Vesicles and Engineered Nanoparticles.Cardiovascular drugs and therapy · 2026Review
- Pharmacological Inhibition of Small Extracellular Vesicle Secretion by ALK5i SD-208 via Lysosomal Rerouting of CD63+ Compartments.Journal of extracellular vesicles · 2026Article
- Extracellular Vesicles in Cardiovascular Disease: Intercellular Signaling, Liquid Biopsy Biomarkers, and Therapeutic Translation.Circulation research · 2026Review
- Stroke Heart Syndrome: Neuroimmune and Metabolic Crosstalk with Conceptual Approaches for Precision Therapeutics.Cardiovascular drugs and therapy · 2026Review
- PRMT2 Aggravates Pressure Overload-induced Cardiac Remodeling by Promoting Endothelial Phenotypic Transition via Snail1 Methylation.Cardiovascular drugs and therapy · 2026Article
- Pericardial Extracellular Vesicles As Drug Carriers: Beyond Native Vesicle Therapy in Heart Failure.Cardiovascular drugs and therapy · 2026Article
- Interaction between Regulated Cell Death Pathways and Core Cellular Processes: Unraveling the Molecular Mechanisms of Cardiotoxicity of Antitumor Drugs.Current treatment options in oncology · 2026Review
- Extracellular vesicles in the heart: mediators of intercellular communication in health and disease in vitro.Cell communication and signaling : CCS · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality globally, accounting for nearly one-third of deaths worldwide. Intercellular communication between cardiomyocytes and non-cardiomyocytes is fundamental to maintaining cardiac homeostasis and adapting to stress or injury. Among the mediators of this communication, extracellular vesicles (EVs) have emerged as pivotal regulators of cardiac function and remodelling, transporting bioactive molecules that reflect the state and origin of their parent cells. This review provides a systems-level synthesis of EV-mediated crosstalk in the heart, integrating evidence from cardiomyocyte- and non-cardiomyocyte-derived EVs, including fibroblast, endothelial, vascular smooth muscle, and immune cell sources. We discuss how these vesicles orchestrate signalling networks that influence cardiac remodelling, injury response, and disease progression. Distinct from prior reviews, our article extends beyond mechanistic summaries to explore the translational continuum of cardiac EVs-from their potential as diagnostic and prognostic biomarkers to emerging therapeutic and bioengineering strategies. Finally, we critically evaluate current technical and regulatory barriers impeding clinical translation, including isolation, characterisation, and validation challenges, and propose a forward-looking roadmap to advance EV-based diagnostics and therapeutics in cardiovascular medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.